Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial

• DOI: 10.1186/s12876-023-02890-5
• Publication Date: 2023-07-24T08:02:33Z
• Authors: Xiao-Dong Zhang; Da-Ya Zhang; Run-Xiang Chen; Shi-Ju Chen; Chen Chen; Fan Zeng; Shi-Mei Huang; Da Li; Fei-Hu Bai
• Keywords: Single Center; Open label; Rescue therapy

This study aimed to evaluate the efficacy, adverse events, patient compliance, and cost of dual therapy with Ilaprazole-amoxicillin (IA) at high dose versus Ilaprazole-amoxicillin-furazolidone-bismuth (IAFB) quadruple for Helicobacter pylori (H.pylori) infection among Chinese patients.